Cullinan Therapeutics Inc (NASDAQ:CGEM) does about 907.49K shares in volume on a normal day but saw 568113 shares change hands in Tuesday’s trading. The company now has a market cap of 946.28M USD. Its current market price is $16.42, marking a decrease of -5.47% compared to the previous close of $17.37. The 52 week high reached by this stock is $30.19 whilst the lowest price level in 52 weeks is $7.64.
Cullinan Therapeutics Inc (CGEM) has a 20-day trading average at $20.89 and the current price is -45.61% off the 52-week high compared with 114.92% distance from its 52-week low. The 50-day simple moving average of the closing price is $22.39 and its 200-day simple moving average is $14.75. If we look at the stock’s price movements over the week, volatility stands at 7.30%, which increases to 7.96% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 28.07 to suggest the stock is oversold.
The consensus objective for the share price is $33.00, suggesting that the stock has a potential upside of 50.24% over the period.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on May 01, 2024 when Stifel initiated the stock to “Buy” and issued a price target of $40. Wedbush initiated its price target at $30.
Cullinan Therapeutics Inc (CGEM) stock is down -13.67% over the week and -27.51% over the past month. Its price is 61.14% year-to-date and 32.21% over the past year.
To reach the target analysts have set, the stock logically needs to grow 50.24 percent from here.
The company has a return on investment of -30.96% and return on equity of -29.05%. The beta has a value of -0.12. Price to book ratio is 1.66.
